Trade Entero Therapeutics Inc - ENTO CFD

Add to favourite

0.4189

5.01%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data

Trading сonditions

Spread

0.0036

Long position overnight fee

-0.023679%

Short position overnight fee

0.001457%

Overnight fee time

21:00 (UTC)

Min traded quantity

0.001

Currency

USD

Margin

5.00%

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	0.3989
Open	0.4431
1-Year Change	-89.22%
Day's Range	0.4102 - 0.4431

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 1, 2025	0.3989	-0.0800	-16.70%	0.4789	0.4789	0.3890
Mar 31, 2025	0.4790	0.0090	1.91%	0.4700	0.4984	0.4700
Mar 28, 2025	0.4792	-0.0397	-7.65%	0.5189	0.5189	0.4788
Mar 27, 2025	0.5339	-0.0111	-2.04%	0.5450	0.5589	0.5332
Mar 26, 2025	0.5339	-0.0050	-0.93%	0.5389	0.5389	0.4989
Mar 25, 2025	0.5489	0.0000	0.00%	0.5489	0.5519	0.5489
Mar 24, 2025	0.5489	-0.0136	-2.42%	0.5625	0.5758	0.5199
Mar 21, 2025	0.5536	0.0577	11.64%	0.4959	0.5677	0.4901
Mar 20, 2025	0.5109	0.0020	0.39%	0.5089	0.5284	0.4901
Mar 19, 2025	0.5259	0.0220	4.37%	0.5039	0.5259	0.5039
Mar 18, 2025	0.5289	0.0176	3.44%	0.5113	0.5568	0.4939
Mar 17, 2025	0.5184	0.0294	6.01%	0.4890	0.5204	0.4789
Mar 14, 2025	0.4809	0.0109	2.32%	0.4700	0.4985	0.4700
Mar 13, 2025	0.4700	-0.0177	-3.63%	0.4877	0.4877	0.4572
Mar 12, 2025	0.4564	0.0075	1.67%	0.4489	0.4884	0.4289
Mar 11, 2025	0.4566	-0.0223	-4.66%	0.4789	0.4914	0.4489
Mar 10, 2025	0.4790	-0.0476	-9.04%	0.5266	0.5266	0.4789
Mar 7, 2025	0.5402	0.0063	1.18%	0.5339	0.5989	0.5089
Mar 6, 2025	0.5589	0.0477	9.33%	0.5112	0.6359	0.5112
Mar 5, 2025	0.5636	0.0748	15.30%	0.4888	0.5636	0.4860

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

1:1
2:1
3:1
5:1
10:1
20:1

Leverage

20:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

First Wave BioPharma, Inc. Company profile

About First Wave BioPharma Inc

First Wave BioPharma, Inc., formerly AzurRx BioPharma, Inc., is a clinical-stage biopharmaceutical company. It is engaged in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. It is focused on advancing a therapeutic development pipeline built around its two technologies: niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The Company's niclosamide portfolio is led by three clinical programs: FW-COV, for COVID-19 gastrointestinal infections; FW-UP, for ulcerative proctitis (UP) and ulcerative proctosigmoiditis; and FW-ICI-AC, for Grade 1 and Grade 2 immune checkpoint inhibitor-associated colitis and diarrhea in advanced oncology patients. It is also advancing FW-EPI (adrulipase) for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.

Financial summary

BRIEF: For the nine months ended 30 September 2021, First Wave BioPharma Inc revenues was not reported. Net loss applicable to common stockholders increased from $23.4M to $73.2M. Higher net loss reflects Research and development expenses - Bala increase of 85% to $8.2M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$8.35 to -$10.31.

Industry:

Biotechnology & Medical Research (NEC)

777 Yamato Road
Suite 502
BOCA RATON
FLORIDA 33431
US